Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Martina Koziar Vasakova"'
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Biodegradable (BD) stents made from polydioxanone have been used only in human airways. These stents combine the advantages of classical tracheal stents, and fewer side effects are expected due to their biocompatibility and their
Externí odkaz:
https://doaj.org/article/8778b4f49e6549ecaab1ec0f86cbf2a6
Autor:
Marie Drosslerova, Martina Sterclova, Alice Taskova, Vladislav Hytych, Eva Richterova, Magdalena Bruzova, Miloslav Spunda, Martin Komarc, Martina Koziar Vasakova
Publikováno v:
Biomedical Papers, Vol 167, Iss 4, Pp 335-339 (2023)
Background. Complex networks of chemokines are part of the immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is unclear whether the concentrations of chemokines at the time of NSCLC (non-small cell lung cancer) diag
Externí odkaz:
https://doaj.org/article/cdb042e436c5401883928ef204a844be
Autor:
Martina Sterclova, Martina Doubkova, Lubica Sykorova, Vladimir Bartos, Monika Zurkova, Vladimira Lostakova, Radka Mokosova, Martina Plackova, Ladislav Lacina, Michaela Cimrova, Radka Bittenglova, Pavlina Lisa, Pavla Musilova, Daniel Dolezal, Jana Psikalova, Petra Ovesna, Martina Koziar Vasakova
Publikováno v:
Pulmonary Medicine, Vol 2024 (2024)
There are limited data on referral rates and the number of patients with idiopathic pulmonary fibrosis (IPF) who are eligible for lung transplantation. The aim of the present study was to assess adherence to the consensus of the International Society
Externí odkaz:
https://doaj.org/article/94d509ca7d934c66ba732b7f4a1dc771
Publikováno v:
American Journal of Respiratory and Critical Care Medicine.
Autor:
Anna L. Peljto, Rachel Z. Blumhagen, Avram D. Walts, Jonathan Cardwell, Julia Powers, Tamera J. Corte, Joanne L. Dickinson, Ian Glaspole, Yuben P. Moodley, Martina Koziar Vasakova, Elisabeth Bendstrup, Jesper R. Davidsen, Raphael Borie, Bruno Crestani, Philippe Dieude, Francesco Bonella, Ulrich Costabel, Gunnar Gudmundsson, Seamas C. Donnelly, Jim Egan, Michael T. Henry, Michael P. Keane, Marcus P. Kennedy, Cormac McCarthy, Aoife N. McElroy, Joshua A. Olaniyi, Katherine M. A. O’Reilly, Luca Richeldi, Paolo M. Leone, Venerino Poletti, Francesco Puppo, Sara Tomassetti, Valentina Luzzi, Nurdan Kokturk, Nesrin Mogulkoc, Christine A. Fiddler, Nikhil Hirani, R. Gisli Jenkins, Toby M. Maher, Philip L. Molyneaux, Helen Parfrey, Rebecca Braybrooke, Timothy S. Blackwell, Peter D. Jackson, Steven D. Nathan, Mary K. Porteous, Kevin K. Brown, Jason D. Christie, Harold R. Collard, Oliver Eickelberg, Elena E. Foster, Kevin F. Gibson, Marilyn Glassberg, Daniel J. Kass, Jonathan A. Kropski, David Lederer, Angela L. Linderholm, Jim Loyd, Susan K. Mathai, Sydney B. Montesi, Imre Noth, Justin M. Oldham, Amy J. Palmisciano, Cristina A. Reichner, Mauricio Rojas, Jesse Roman, Neil Schluger, Barry S. Shea, Jeffrey J. Swigris, Paul J. Wolters, Yingze Zhang, Cecilia M. A. Prele, Juan I. Enghelmayer, Maria Otaola, Christopher J. Ryerson, Mauricio Salinas, Martina Sterclova, Tewodros H. Gebremariam, Marjukka Myllärniemi, Roberto G. Carbone, Haruhiko Furusawa, Masaki Hirose, Yoshikazu Inoue, Yasunari Miyazaki, Ken Ohta, Shin Ohta, Tsukasa Okamoto, Dong Soon Kim, Annie Pardo, Moises Selman, Alvaro U. Aranda, Moo Suk Park, Jong Sun Park, Jin Woo Song, Maria Molina-Molina, Lurdes Planas-Cerezales, Gunilla Westergren-Thorsson, Albert V. Smith, Ani W. Manichaikul, John S. Kim, Stephen S. Rich, Elizabeth C. Oelsner, R. Graham Barr, Jerome I. Rotter, Josee Dupuis, George O’Connor, Ramachandran S. Vasan, Michael H. Cho, Edwin K. Silverman, Marvin I. Schwarz, Mark P. Steele, Joyce S. Lee, Ivana V. Yang, Tasha E. Fingerlin, David A. Schwartz
Rationale: Idiopathic pulmonary fibrosis is a rare, irreversible, and progressive disease of the lungs. Common genetic variants, in addition to non-genetic factors, have been consistently associated with IPF. Rare variants identified by candidate gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0670c24aedc8efa23979477ed15d39b
http://hdl.handle.net/10044/1/101620
http://hdl.handle.net/10044/1/101620
Autor:
Andrew Churg, Henry Tazelaar, Radoslav Matej, Martina Koziar Vasakova, Brian Stewart, Divya Patel, Ernesto Duarte, Diana C. Gomez Manjarres, Mehta J. Hiren, Joanne L. Wright
Publikováno v:
Modern Pathology. :100221
Autor:
Marianna Štefániková, Martina Doubková, Petra Ovesná, Martina Šterclová, Ladislav Lacina, Monika Žurková, Martina Plačková, Vladimír Bartoš, Ivana Janíčková, Radka Bittenglová, Jan Anton, Ľubica Sýkorová, Vladimíra Lošťáková, Pavlína Musilová, Hana Šuldová, Radka Mokošová, Jurij Didyk, Lenka Šišáková, Pavlína Lisá, Jaroslav Lněnička, Hana Dařičková, Daniel Doležel, Jana Pšikalová, Richard Tyl, Renata Králová, Martina Koziar Vašáková
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Introduction The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry. Patients/m
Externí odkaz:
https://doaj.org/article/354e93acae574d0789b4d40b679b4189
Autor:
Brian Ward, Martina Koziar Vašáková, Carlos Robalo Cordeiro, Arzu Yorgancioğlu, Joanna Chorostowska-Wynimko, Torsten Gerriet Blum, Hans-Ulrich Kauczor, Miroslav Samarzija, Claudia Henschke, Craig Wheelock, Jonathan Grigg, Zorana Jovanovic Andersen, Vladimír Koblížek, Ondřej Májek, Mikaela Odemyr, Pippa Powell, Luis M. Seijo
Publikováno v:
ERJ Open Research, Vol 9, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/dd514ad2720742fab94fc4622f91b87a
Autor:
Ondřej Májek, Jakub Gregor, Nesrin Mogulkoć, Katarzyna Lewandowska, Martina Šterclová, Veronika Müller, Marta Hájková, Mordechai R Kramer, Jasna Tekavec-Trkanjec, Dragana Jovanović, Michael Studnicka, Natalia Stoeva, Klaus-Uwe Kirchgässler, Simona Littnerová, Ladislav Dušek, Martina Koziar Vašáková
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0273854 (2022)
BackgroundThere is no clear evidence whether pirfenidone has a benefit in patients with probable or possible UIP, i.e. when idiopathic pulmonary fibrosis (IPF) is diagnosed with a lower degree of diagnostic certainty. We report on outcomes of treatme
Externí odkaz:
https://doaj.org/article/62d03fd7fced4bb68c72565e31432e8a